Business
Stay True to Our Original Aspiration, Forge Ahead into the Future｜Alphamab Oncology 2025 R&D Day Successfully Held
On December 8, 2025, Alphamab Oncology (Stock Code: 9966.HK) successfully held its "Stay True to Our Original Aspiration, Forge Ahead into the Future" 2025 R&D Day in Shanghai. The event focused on the latest advancements in the field of antibody-drug conjugates (ADCs), comprehensively showcasing the company's R&D achievements in bispecific ADCs and dual-payload ADCs. It also shared a highly differentiated and globally competitive product pipeline and clinical development strategy, while outlini
About this update from Alphamab Oncology
[{"type":"text","content":"SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- On December 8, 2025, Alphamab Oncology (Stock Code: 9966.HK) successfully held its "Stay True to Our Original Aspiration, Forge Ahead into the Future" 2025 R&D Day in Shanghai. The event focused on the latest advancements in the field of antibody-drug conjugates (ADCs), comprehensively showcasing the company's R&D achievements in bispecific ADCs and dual-payload ADCs. It also shared a highly differentiated and globally competitive product pipeline and clinical development strategy, while outlining the multidimensional evolution of its world-leading technology platforms and the future blueprint for ADC therapies.","length":691,"tagName":"p"},{"type":"text","content":"The event featured attendance of several distinguished experts, including Professor Li Zhang from the Sun Yat-sen University Cancer Center, Professor Chang Chen from the Shanghai Pulmonary Hospital, Professor Jian Zhang from the Fudan University Shanghai Cancer Center, and Professor Suiwen Ye from the Sun Yat-sen Memorial Hospital. Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, along with representatives from the company's management team, also participated in the event. The thematic presentations and in-depth discussions during the conference attracted hundreds of guests from academia, industry, and the investment sector, with over a thousand participants joining online. This robust engagement fully reflects the industry's significant interest in the company's R&D capabilities and innovation strategy.","length":834,"tagName":"p"},{"type":"text","content":"Professor Li Zhang provided a systematic review of the development history of ADC drugs and advancements in the treatment of non-small cell lung cancer (NSCLC). Drawing on clinical trial cases of ADC therapies, he elaborated on the current landscape and challenges in this field: drug resistance and insufficient response rates remain major challenges in lung cancer treatment. ADCs, with their "precision targeting + high efficacy killing" mechanism, have emerged as a significant breakthrough direction. However, issues such as target heterogeneity and endocytosis efficiency remain current difficulties. Professor Zhang particularly emphasized that JSKN016's dual-target design helps broaden tumor recognition and en...